Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | ERN1 | O75460 | 1/20 | 0.35 |
| ▸ | CYP2A6 | P11509 | 4/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.34 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | PIM1 | P11309 | 1/20 | 0.31 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.31 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.31 |
| ▸ | BRSK1 | Q8TDC3 | 1/20 | 0.31 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.30 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.30 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.30 |
| ▸ | PTPRC | P08575 | 1/20 | 0.30 |
| ▸ | PLG | P00747 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5828240 | 0.79 | ALDH1A1 (0.40) | ALDH1A1HSD17B10TDP1ERN1CYP2A6 | |
| SCHEMBL5828810 | 0.77 | RARB (0.44) | ALDH1A1HSD17B10TDP1MAPK1 | |
| SCHEMBL5827711 | 0.76 | PDCD1 (0.38) | ALDH1A1CA12CA2CA9MAPK1 | |
| SCHEMBL5827840 | 0.76 | ERN1 (0.42) | ALDH1A1HSD17B10TDP1ERN1 | |
| SCHEMBL5828259 | 0.75 | CYP2A6 (0.31) | CYP2A6 | |
| SCHEMBL31009461 | 0.75 | ALDH1A1 (0.52) | ALDH1A1HSD17B10TDP1GLO1AOC3 | |
| SCHEMBL4330234 | 0.75 | ALDH1A1 (0.52) | ALDH1A1HSD17B10TDP1GLO1AOC3 | |
| SCHEMBL4033357 | 0.73 | ALDH1A1 (0.69) | ALDH1A1HSD17B10TDP1CYP2A6MAPK1 | |
| SCHEMBL5828129 | 0.72 | SIRT2 (0.49) | ALDH1A1HSD17B10SIRT1 | |
| SCHEMBL30132116 | 0.70 | ALDH1A1 (0.63) | ALDH1A1HSD17B10TDP1ERN1CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7153875-B2 | Heterocyclic derivatives for the treatment of cancer and other proliferative diseases | INCYTE SAN DIEGO (US) | 2006-12-26 | — | — | US | disclosed |
| EP-1385465-A4 | HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF CANCER AND OTHER PROLIFERATIVE DISEASES | INCYTE SAN DIEGO INC (US) | 2005-09-07 | — | — | EP | disclosed |
| EP-1385465-A2 | HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF CANCER AND OTHER PROLIFERATIVE DISEASES | Incyte San Diego, Inc. (US) | 2004-02-04 | — | — | EP | disclosed |
| US-20020143182-A1 | Heterocyclic derivatives for the treatment of cancer and other proliferative diseases | INCYTE GENOMICS, INC. | 2002-10-03 | — | — | US | disclosed |
| WO-2002072009-A2 | HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF CANCER AND OTHER PROLIFERATIVE DISEASES | MAXIA PHARMACEUTICALS, INC. (US) | 2002-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020143182-A1 | Heterocyclic derivatives for the treatment of cancer and other proliferative diseases | CCNY, HRAS, AHR | ALDH1A1 2952/4885HSD17B10 524/4885TDP1 4233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.